Sugi Predict

Sugi Predict / Compounds / SCHEMBL13675998

SCHEMBL13675998

SCHEMBL13675998

CCOC(=O)C1CN(C)c2cc(NC(=O)CCc3ccc(C(C)(C)C)cc3)ccc2O1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 2/20 0.55
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 5/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13676008 0.88 TRPV1 (0.59) TRPV1ALDH1A1TSHRNPC1RAB9A
SCHEMBL13676041 0.86 TRPV1 (0.57) TRPV1ALDH1A1POLBTSHRMAPT
SCHEMBL13676005 0.86 TRPV1 (0.56) TRPV1ALDH1A1TSHRNPC1RAB9A
SCHEMBL13676057 0.83 TRPV1 (0.59) TRPV1ALDH1A1TSHRNPC1RAB9A
SCHEMBL13676035 0.82 TRPV1 (0.55) TRPV1ALDH1A1POLBTSHRMAPT
SCHEMBL13675720 0.82 TRPV1 (0.54) TRPV1KMT2ATSHRMAPTNPC1
SCHEMBL13676132 0.77 TRPV1 (0.56) TRPV1ALDH1A1POLBTSHRMAPT
SCHEMBL13676142 0.77 TRPV1 (0.54) TRPV1ALDH1A1POLBTSHRMAPT
SCHEMBL13676065 0.77 TRPV1 (0.73) TRPV1KMT2AALDH1A1POLBTSHR
SCHEMBL13676131 0.76 TRPV1 (0.56) TRPV1ALDH1A1TSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 — — US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 — — US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 — — US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 — — US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 — — US disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 — — EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885KMT2A 3777/4885ALDH1A1 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.